(+)-schisandrin B multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYP39A1 mRNA] CTD PMID:31150632 (24S)-24-hydroxycholesterol increases metabolic processing ISO RGD:1316686 6480464 CYP39A1 protein results in increased metabolism of 24-hydroxycholesterol CTD PMID:10748047 1,2-dichloroethane increases expression ISO RGD:1316686 6480464 ethylene dichloride results in increased expression of CYP39A1 mRNA CTD PMID:28189721 , PMID:28960355 1,2-dimethylhydrazine decreases expression ISO RGD:1316686 6480464 1, 2-Dimethylhydrazine results in decreased expression of CYP39A1 mRNA CTD PMID:22206623 1H-pyrazole decreases expression ISO RGD:1316686 6480464 pyrazole results in decreased expression of CYP39A1 mRNA CTD PMID:17945193 2,2',4,4',5,5'-hexachlorobiphenyl increases expression ISO RGD:1316686 6480464 2 more ... CTD PMID:21851831 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:1316686 6480464 [Tetrachlorodibenzodioxin co-treated with 2 more ... CTD PMID:28433925 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1316685 6480464 Tetrachlorodibenzodioxin results in increased expression of CYP39A1 mRNA CTD PMID:20106945 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of CYP39A1 mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1316686 6480464 [Tetrachlorodibenzodioxin co-treated with 2 more ... CTD PMID:28433925 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1316686 6480464 Tetrachlorodibenzodioxin affects the expression of CYP39A1 mRNA CTD PMID:28922406 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1316686 6480464 Tetrachlorodibenzodioxin results in increased expression of CYP39A1 mRNA CTD PMID:28213091 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of CYP39A1 mRNA CTD PMID:22298810 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1316686 6480464 Tetrachlorodibenzodioxin results in decreased expression of CYP39A1 mRNA CTD PMID:19770486 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of CYP39A1 mRNA CTD PMID:21346803 2-hydroxypropanoic acid decreases expression ISO RGD:1316685 6480464 Lactic Acid results in decreased expression of CYP39A1 mRNA CTD PMID:30851411 3,3',5,5'-tetrabromobisphenol A decreases expression ISO RGD:1316686 6480464 tetrabromobisphenol A results in decreased expression of CYP39A1 mRNA CTD PMID:25172293 4,4'-sulfonyldiphenol increases expression ISO RGD:1316686 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of CYP39A1 mRNA CTD PMID:30951980 4-hydroxyphenyl retinamide increases expression ISO RGD:1316686 6480464 Fenretinide results in increased expression of CYP39A1 mRNA CTD PMID:28973697 acetamide decreases expression EXP 6480464 acetamide results in decreased expression of CYP39A1 mRNA CTD PMID:31881176 acrylamide increases expression ISO RGD:1316685 6480464 Acrylamide results in increased expression of CYP39A1 mRNA CTD PMID:32763439 aflatoxin B1 affects expression ISO RGD:1316685 6480464 Aflatoxin B1 affects the expression of CYP39A1 protein CTD PMID:20106945 aflatoxin B1 decreases expression ISO RGD:1316685 6480464 Aflatoxin B1 results in decreased expression of CYP39A1 mRNA CTD PMID:22100608 , PMID:27153756 aflatoxin B1 decreases expression ISO RGD:1316686 6480464 Aflatoxin B1 results in decreased expression of CYP39A1 mRNA CTD PMID:19770486 aldrin decreases expression ISO RGD:1316686 6480464 Aldrin results in decreased expression of CYP39A1 mRNA CTD PMID:18579281 all-trans-retinoic acid increases expression ISO RGD:1316685 6480464 Tretinoin results in increased expression of CYP39A1 mRNA CTD PMID:21934132 amiodarone decreases expression ISO RGD:1316686 6480464 Amiodarone results in decreased expression of CYP39A1 mRNA CTD PMID:24535564 antirheumatic drug increases expression ISO RGD:1316685 6480464 Antirheumatic Agents results in increased expression of CYP39A1 mRNA CTD PMID:24449571 arsenite(3-) decreases expression ISO RGD:1316686 6480464 arsenite results in decreased expression of CYP39A1 mRNA CTD PMID:18929588 arsenous acid decreases expression ISO RGD:1316685 6480464 Arsenic Trioxide results in decreased expression of CYP39A1 mRNA CTD PMID:15761015 atorvastatin calcium increases expression ISO RGD:1316686 6480464 Atorvastatin results in increased expression of CYP39A1 mRNA CTD PMID:25278499 atrazine affects methylation EXP 6480464 Atrazine affects the methylation of CYP39A1 gene CTD PMID:28931070 belinostat increases expression ISO RGD:1316685 6480464 belinostat results in increased expression of CYP39A1 mRNA CTD PMID:27188386 benzo[a]pyrene increases expression ISO RGD:1316685 6480464 Benzo(a)pyrene results in increased expression of CYP39A1 mRNA CTD PMID:16545412 benzo[a]pyrene increases expression ISO RGD:1316686 6480464 Benzo(a)pyrene results in increased expression of CYP39A1 protein CTD PMID:34472326 benzo[a]pyrene decreases expression ISO RGD:1316685 6480464 Benzo(a)pyrene results in decreased expression of CYP39A1 mRNA CTD PMID:32234424 benzo[a]pyrene increases methylation ISO RGD:1316685 6480464 Benzo(a)pyrene results in increased methylation of CYP39A1 promoter CTD PMID:27901495 benzo[a]pyrene decreases methylation ISO RGD:1316686 6480464 Benzo(a)pyrene results in decreased methylation of CYP39A1 exon, Benzo(a)pyrene results in decreased methylation of CYP39A1 intron CTD PMID:27901495 benzo[a]pyrene multiple interactions ISO RGD:1316686 6480464 AHR protein affects the reaction [Benzo(a)pyrene affects the expression of CYP39A1 mRNA] CTD PMID:22228805 benzo[a]pyrene decreases expression ISO RGD:1316686 6480464 Benzo(a)pyrene results in decreased expression of CYP39A1 mRNA CTD PMID:19770486 , PMID:22228805 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:1316686 6480464 [Tetrachlorodibenzodioxin co-treated with 2 more ... CTD PMID:28433925 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of CYP39A1 mRNA CTD PMID:25181051 more ... bisphenol A increases expression ISO RGD:1316686 6480464 bisphenol A results in increased expression of CYP39A1 mRNA CTD PMID:30951980 bisphenol A multiple interactions ISO RGD:1316686 6480464 [Tetrachlorodibenzodioxin co-treated with 2 more ... CTD PMID:28433925 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of CYP39A1 gene CTD PMID:28505145 bisphenol F increases expression ISO RGD:1316686 6480464 bisphenol F results in increased expression of CYP39A1 mRNA CTD PMID:30951980 cadmium sulfate multiple interactions ISO RGD:1316686 6480464 cadmium sulfate affects the reaction [MTF1 affects the expression of CYP39A1 mRNA] CTD PMID:16221973 carbamazepine increases expression ISO RGD:1316685 6480464 Carbamazepine results in increased expression of CYP39A1 mRNA CTD PMID:17112801 carbon nanotube decreases expression ISO RGD:1316686 6480464 Nanotubes more ... CTD PMID:25554681 chloroprene increases expression ISO RGD:1316686 6480464 Chloroprene results in increased expression of CYP39A1 mRNA CTD PMID:23125180 choline multiple interactions ISO RGD:1316686 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CYP39A1 mRNA CTD PMID:20938992 ciguatoxin CTX1B affects expression ISO RGD:1316686 6480464 Ciguatoxins affects the expression of CYP39A1 mRNA CTD PMID:18353800 cisplatin multiple interactions ISO RGD:1316686 6480464 [Cisplatin co-treated with RELB mutant form co-treated with TNF protein] results in decreased expression of CYP39A1 mRNA CTD PMID:23625948 cyclosporin A decreases expression ISO RGD:1316685 6480464 Cyclosporine results in decreased expression of CYP39A1 mRNA CTD PMID:20106945 cyclosporin A increases expression ISO RGD:1316685 6480464 Cyclosporine results in increased expression of CYP39A1 mRNA CTD PMID:27989131 diarsenic trioxide decreases expression ISO RGD:1316685 6480464 Arsenic Trioxide results in decreased expression of CYP39A1 mRNA CTD PMID:15761015 dichloroacetic acid decreases expression ISO RGD:1316686 6480464 Dichloroacetic Acid results in decreased expression of CYP39A1 mRNA CTD PMID:28962523 diclofenac increases expression ISO RGD:1316686 6480464 Diclofenac results in increased expression of CYP39A1 mRNA CTD PMID:26934552 dorsomorphin multiple interactions ISO RGD:1316685 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP39A1 mRNA CTD PMID:27188386 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of CYP39A1 mRNA CTD PMID:29391264 epoxiconazole increases expression ISO RGD:1316686 6480464 epoxiconazole results in increased expression of CYP39A1 mRNA CTD PMID:35436446 ethanol increases expression ISO RGD:1316686 6480464 Ethanol results in increased expression of CYP39A1 mRNA CTD PMID:19167417 flutamide decreases expression EXP 6480464 Flutamide results in decreased expression of CYP39A1 mRNA CTD PMID:24793618 folic acid multiple interactions ISO RGD:1316686 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CYP39A1 mRNA CTD PMID:20938992 fulvestrant increases methylation ISO RGD:1316685 6480464 Fulvestrant results in increased methylation of CYP39A1 gene CTD PMID:31601247 glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of CYP39A1 mRNA CTD PMID:24136188 L-methionine multiple interactions ISO RGD:1316686 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CYP39A1 mRNA CTD PMID:20938992 lipopolysaccharide decreases expression ISO RGD:1316686 6480464 Lipopolysaccharides results in decreased expression of CYP39A1 mRNA CTD PMID:27339419 lithocholic acid multiple interactions ISO RGD:1316686 6480464 [1 more ... CTD PMID:19196849 methylmercury chloride decreases expression ISO RGD:1316685 6480464 methylmercuric chloride results in decreased expression of CYP39A1 mRNA CTD PMID:28001369 N,N-diethyl-m-toluamide multiple interactions EXP 6480464 [Permethrin co-treated with DEET] results in increased methylation of CYP39A1 gene CTD PMID:33148267 N-nitrosodiethylamine increases expression ISO RGD:1316686 6480464 Diethylnitrosamine results in increased expression of CYP39A1 mRNA CTD PMID:24535843 nickel atom decreases expression ISO RGD:1316685 6480464 Nickel results in decreased expression of CYP39A1 mRNA CTD PMID:24768652 , PMID:25583101 niclosamide increases expression ISO RGD:1316685 6480464 Niclosamide results in increased expression of CYP39A1 mRNA CTD PMID:28284560 obeticholic acid decreases expression ISO RGD:1316685 6480464 obeticholic acid results in decreased expression of CYP39A1 mRNA CTD PMID:27939613 ochratoxin A increases expression ISO RGD:1316685 6480464 ochratoxin A results in increased expression of CYP39A1 mRNA CTD PMID:30559759 paracetamol decreases expression ISO RGD:1316685 6480464 Acetaminophen results in decreased expression of CYP39A1 mRNA CTD PMID:26690555 , PMID:29067470 paraquat decreases expression EXP 6480464 Paraquat results in decreased expression of CYP39A1 mRNA CTD PMID:32680482 pentachlorophenol increases expression ISO RGD:1316686 6480464 Pentachlorophenol results in increased expression of CYP39A1 mRNA CTD PMID:23892564 perfluorononanoic acid multiple interactions ISO RGD:1316686 6480464 [Dietary Fats co-treated with perfluoro-n-nonanoic acid] results in decreased expression of CYP39A1 mRNA CTD PMID:33483757 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1316686 6480464 [Dietary Fats co-treated with perfluorooctane sulfonic acid] results in decreased expression of CYP39A1 mRNA CTD PMID:33483757 perfluorooctanoic acid decreases expression ISO RGD:1316685 6480464 perfluorooctanoic acid results in decreased expression of CYP39A1 mRNA CTD PMID:32588087 permethrin multiple interactions EXP 6480464 [Permethrin co-treated with DEET] results in increased methylation of CYP39A1 gene CTD PMID:33148267 phenobarbital affects expression ISO RGD:1316686 6480464 Phenobarbital affects the expression of CYP39A1 mRNA CTD PMID:23091169 phenobarbital multiple interactions ISO RGD:1316686 6480464 [Phenobarbital co-treated with Lithocholic Acid] results in increased expression of CYP39A1 mRNA, NR1I3 protein promotes the reaction [[Phenobarbital co-treated with Lithocholic Acid] results in increased expression of CYP39A1 mRNA] CTD PMID:19196849 pirinixic acid multiple interactions ISO RGD:1316686 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CYP39A1 mRNA, PPARA protein inhibits the reaction [pirinixic acid results in increased expression of CYP39A1 mRNA] CTD PMID:17950772 , PMID:19710929 pirinixic acid decreases expression ISO RGD:1316686 6480464 pirinixic acid results in decreased expression of CYP39A1 mRNA CTD PMID:20813756 , PMID:23811191 pirinixic acid increases expression ISO RGD:1316686 6480464 pirinixic acid results in increased expression of CYP39A1 mRNA CTD PMID:17950772 pirinixic acid multiple interactions ISO RGD:1316685 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of CYP39A1 mRNA CTD PMID:19710929 rac-lactic acid decreases expression ISO RGD:1316685 6480464 Lactic Acid results in decreased expression of CYP39A1 mRNA CTD PMID:30851411 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of CYP39A1 mRNA CTD PMID:28374803 SB 431542 multiple interactions ISO RGD:1316685 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP39A1 mRNA CTD PMID:27188386 silver atom decreases expression ISO RGD:1316686 6480464 Silver results in decreased expression of CYP39A1 mRNA CTD PMID:27131904 silver(0) decreases expression ISO RGD:1316686 6480464 Silver results in decreased expression of CYP39A1 mRNA CTD PMID:27131904 simvastatin decreases expression EXP 6480464 Simvastatin results in decreased expression of CYP39A1 mRNA CTD PMID:25055962 sodium arsenite decreases expression ISO RGD:1316685 6480464 sodium arsenite results in decreased expression of CYP39A1 mRNA CTD PMID:34032870 sulforaphane increases expression ISO RGD:1316685 6480464 sulforaphane results in increased expression of CYP39A1 mRNA CTD PMID:31838189 tetrachloromethane increases expression ISO RGD:1316686 6480464 Carbon Tetrachloride results in increased expression of CYP39A1 mRNA CTD PMID:17484886 , PMID:31919559 tetrachloromethane multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYP39A1 mRNA] CTD PMID:31150632 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of CYP39A1 mRNA CTD PMID:31150632 thimerosal increases expression ISO RGD:1316685 6480464 Thimerosal results in increased expression of CYP39A1 mRNA CTD PMID:27188386 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of CYP39A1 mRNA CTD PMID:23411599 more ... trichloroethene increases expression EXP 6480464 Trichloroethylene results in increased expression of CYP39A1 mRNA CTD PMID:33387578 trichostatin A decreases expression ISO RGD:1316685 6480464 trichostatin A results in decreased expression of CYP39A1 mRNA CTD PMID:24935251 trichostatin A increases expression ISO RGD:1316685 6480464 trichostatin A results in increased expression of CYP39A1 mRNA CTD PMID:24935251 , PMID:27188386 Triptolide decreases expression ISO RGD:1316686 6480464 triptolide results in decreased expression of CYP39A1 mRNA CTD PMID:32835833 tunicamycin decreases expression ISO RGD:1316686 6480464 Tunicamycin results in decreased expression of CYP39A1 mRNA CTD PMID:17127020 valproic acid affects expression ISO RGD:1316686 6480464 Valproic Acid affects the expression of CYP39A1 mRNA CTD PMID:17292431 valproic acid increases expression EXP 6480464 Valproic Acid results in increased expression of CYP39A1 mRNA CTD PMID:35594946 valproic acid decreases expression ISO RGD:1316686 6480464 Valproic Acid results in decreased expression of CYP39A1 mRNA CTD PMID:24535564 valproic acid affects expression ISO RGD:1316685 6480464 Valproic Acid affects the expression of CYP39A1 mRNA CTD PMID:25979313 valproic acid increases expression ISO RGD:1316686 6480464 Valproic Acid results in increased expression of CYP39A1 mRNA CTD PMID:24896083 valproic acid multiple interactions ISO RGD:1316685 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP39A1 mRNA CTD PMID:27188386 valproic acid increases expression ISO RGD:1316685 6480464 Valproic Acid results in increased expression of CYP39A1 mRNA CTD PMID:23179753 more ... vorinostat increases expression ISO RGD:1316685 6480464 vorinostat results in increased expression of CYP39A1 mRNA CTD PMID:27188386